Sedlacek, Dalibor

Up a level
Export as [feed] RSS
Group by: Item Type | No Grouping
Number of items: 4.

Journal Article

Lundgren, Jens D; Babiker, Abdel G; Sharma, Shweta; Grund, Birgit; Phillips, Andrew N; Matthews, Gail; Kan, Virginia L; Aagaard, Bitten; Abo, Inka; Alston, Beverly; Arenas-Pinto, Alejandro; Avihingsanon, Anchalee; Badal-Faesen, Sharlaa; Brites, Carlos; Carey, Cate; Casseb, Jorge; Clarke, Amanda; Collins, Simon; Corbelli, Giulio Maria; Dao, Sounkalo; ... (2023). Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection. NEJM Evidence, 2(3) NEJM Group 10.1056/evidoa2200302

Mocroft, Amanda; Geressu, Adam; Beguelin, Charles; Llibre, Josep M; Lazarus, Jeffrey V; Tomazic, Janez; Smidt, Jelena; Parczewski, Milosz; Brännström, Johanna; Sedlacek, Dalibor; Degen, Olaf; van der Valk, Marc; Paduta, Dzmitry; Flamholc, Leo; Schmid, Patrick; Orkin, Chloe; Nielsen, Lars N; Hoffmann, Christian; Beniowski, Marek; Oprea, Cristiana; ... (2023). The role of HIV/hepatitis B virus/hepatitis C virus RNA+ triple infection in end-stage liver disease and all-cause mortality in Europe. AIDS, 37(1), pp. 91-103. Wolters Kluwer Health 10.1097/QAD.0000000000003406

Mocroft, Amanda; Ryom, Lene; Oprea, Cristiana; Li, Qiuju; Rauch, Andri; Boesecke, Christoph; Uzdaviniene, Vilma; Sedlacek, Dalibor; Llibre, Josep M; Lacombe, Karine; Nielsen, Lars N; Florence, Eric; Aho, Inka; Chkhartishvili, Nikoloz; Szlavik, János; Dragovic, Gordana; Leen, Clifford; Sambatakou, Helen; Staub, Therese; Laguno, Montse; ... (2020). Influence of hepatitis C virus co-infection and hepatitis C virus treatment on risk of chronic kidney disease in HIV-positive persons. AIDS, 34(10), pp. 1485-1495. Lippincott Williams & Wilkins 10.1097/QAD.0000000000002570

Boatman, Jeffrey A; Baker, Jason V; Emery, Sean; Furrer, Hansjakob; Mushatt, David M; Sedlacek, Dalibor; Lundgren, Jens D; Neaton, James D (2019). Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression among Participants Initiating Antiretroviral Treatment with CD4+ Counts > 500 cells/mm3: Findings from the Strategic Timing of AntiRetroviral Treatment (START) Trial. Journal of acquired immune deficiency syndromes JAIDS, 81(1), pp. 10-17. Wolters Kluwer Health 10.1097/QAI.0000000000001967

This list was generated on Sun May 5 17:23:20 2024 CEST.
Provide Feedback